Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 21 to 30 of 2003

TitleReference numberPublishedLast updated
Clascoterone for treating acne vulgaris in people 12 years and over (terminated appraisal)TA1105
Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years (terminated appraisal)TA1104
Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitorTA1103
Rehabilitation for chronic neurological disorders including acquired brain injuryNG252
Artificial intelligence (AI) technologies to aid opportunistic detection of vertebral fragility fractures: early value assessmentHTE34
Sparsentan for treating primary IgA nephropathyTA1074
Targeted-release budesonide for treating primary IgA nephropathyTA937
Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and overTA1101
Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapyTA1099
Mirabegron for treating neurogenic detrusor overactivity in people 3 to 17 years (terminated appraisal)TA1100

Results per page

  1. 10
  2. 25
  3. 50
  4. All